|
CAS番号. | 314-19-2 |
化学名: | (-)-アポモルフィン·塩酸塩 |
别名: | (-)-アポモルフィン·塩酸塩;(6aR)-5,6,6aβ,7-テトラヒドロ-6-メチル-4H-ジベンゾ[de,g]キノリン-10,11-ジオール·塩酸塩;アポモルフィン·塩酸塩;アポモルフィン塩酸塩;(6aR)-5,6,6a,7-テトラヒドロ-6-メチル-4H-ジベンゾ[de,g]キノリン-10,11-ジオール·塩酸塩;塩酸アポモルフィン |
英語化学名: | APOMORPHINE HYDROCHLORIDE |
英語别名: | (r)-id;UPRIMA;R(–)-APO;NSC 11442;(theta)-id;(-)-APO H CL;APOMORPHINE HCL;apomorphinechloride;apomorphiniumchloride;Apomorphine hydrochoride |
CBNumber: | CB8357092 |
分子式: | C17H18ClNO2 |
分子量: | 303.78 |
MOL File: | 314-19-2.mol |
|
|
|
|
(-)-アポモルフィン·塩酸塩 化学特性,用途語,生産方法 |
生物活性
Prototypical dopamine agonist (pK i values are 6.43, 7.08, 7.59, 8.36 and 7.83 for human recombinant D 1 , D 2L , D 3 , D 4 and D 5 receptors respectively). Produces biphasic effects on locomotor activity, and displays anti-Parkinsonian and neuroprotective actions following systemic administration in vivo . |
|
|
(-)-アポモルフィン·塩酸塩 上流と下流の製品情報 |
原材料
|
準備製品
|
(-)-アポモルフィン·塩酸塩 生産企業 Global( 32)Suppliers |
|
|
|
|
314-19-2
(-)-apomorphiniumhydrochloride
(r)-id
(theta)-id
11-diol,6-methyl-6a-beta-noraporphine-1hydrochloride
6a-beta-aporphine-10,11-diol,hydrochloride
apomorphinechloride
apomorphiniumchloride
g)quinoline-10,11-diol,5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo(dhydrochlor
g]quinoline-10,11-diol,5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo[dhydrochlor
(R)-(-)-APOMORPHINE HYDROCHLORIDE
(R)-5,6,6A,7-TETRAHYDRO-6-METHYL-4H-DIBENZO[DE,G]QUINOLINE-10,11-DIOL HYDROCHLORIDE
R(-)-10,11-DIHYDROXYAPORPHINE HYDROCHLORIDE
UPRIMA
APOMORPHINE HCL
APOMORPHINE HYDROCHLORIDE
(-)-APO H CL
4H-Dibenzode,gquinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, (6aR)-
Apomorphine hydrochoride
g)quinoline-10,11-diol,5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo(dhydr
R()-Apomorphine hydrochloride,R(–)-10,11-Dihydroxyaporphine, R(–)-APO
NSC 11442
R(–)-APO
(-)-アポモルフィン·塩酸塩
(6aR)-5,6,6aβ,7-テトラヒドロ-6-メチル-4H-ジベンゾ[de,g]キノリン-10,11-ジオール·塩酸塩
アポモルフィン·塩酸塩
アポモルフィン塩酸塩
(6aR)-5,6,6a,7-テトラヒドロ-6-メチル-4H-ジベンゾ[de,g]キノリン-10,11-ジオール·塩酸塩
塩酸アポモルフィン
Parkinson病治療薬
ドーパミン作動薬
催吐薬
|